Chemotherapy by Infusion for Malignant Bone Tumors
One of the important factors for determining the destruction of human cancer cells by chemotherapeutic agents is the proliferative state of the tumor cell population at the time of drug exposure. Two classes of chemotherapeutic agents are available: one is nonspecific or cell-cycle specific; the second is phase specific (Valeriote and Von Pulten, 1975). Phase-specific agents kill cells in one phase of the cell cycle and have little effect on cells in other phases, whereas cell cycle specific agents kill cells throughout the cell cycle and are less cytotoxic to cells in the nonproliferative state. These differences in cell··cycle kinetics are responsible for the differences in tumor response to various anticancer agents. For example, little or no response would be noted with a cell cycle specific drug in a tumor with a large fraction of cells in the resting or G0 phase (low grade or mitotically inactive tumors). If the drug were administered frequently, however, or if the exposure were prolonged, then more normal hemopoietic stem cells would be destroyed, causing increasing toxicity and intolerable side effects to nonmalignant cells that would be mitotically active.
KeywordsLimb Salvage Superficial Femoral Artery Malignant Bone Tumor Isolate Limb Perfusion Local Tumor Recurrence
Unable to display preview. Download preview PDF.
- 1.Benjamin, R., Hegha, H., Mackay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S., Blumenschein, G., and Freireich, E.: Reduction of adriamycin cardiac toxicity using a prolonged continuous intravenous infusion. Proc. AACR 22, 179, 1981.Google Scholar
- 6.Jaffe, N., Chuang, V., Wallace, S., Ayala, A., Murray, J., Romsdahl, M., and Benjamin, R.: Osteosarcoma: Control of the primary tumor with intraarterial cisplatinum. Proc. AACR 21, 197, 1980.Google Scholar
- 10.Pratt, Y.: Intraarterial chemotherapy in cancer treatment—selected abstracts. International Cancer Research Databank Program. National Cancer Institute, U.S. Department of Health and Health Services, September 1982.Google Scholar
- 11.Rosen, G., Caparros, B., Huvos, A., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R., Lane, J.J. and Metha, B.: Preoperative chemotherapy for osteosarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to chemotherapy. Cancer 49, 1221, 1982.PubMedCrossRefGoogle Scholar